Dr Reddy's aims to launch generic obesity drug at 60% discount
ReutersFeb 17, 2026 12:43 PM
By Rishika Sadam and Sriparna Roy
HYDERABAD, Feb 17 (Reuters) - Indian drugmaker Dr Reddy's laboratories REDY.NS aims to launch a generic version of Novo Nordisk's NOVOb.CO blockbuster weight loss drug Wegovy, subject to approval, at a price about 60% lower than the branded version, co-chairman and managing director GV Prasad told Reuters on Tuesday.
The company last month received an approval from India's drug regulator to manufacture and sell the generic version of blockbuster diabetes drug Ozempic and said it was awaiting approval for Wegovy.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
The Magnificent Seven: What They Are, How They Performed in 2025, and Which Will Be the Best in 2026?
TradingKey - The Magnificent Seven refers to the seven best tech stocks in 2023. These are Apple (AAPL), Microsoft (MSFT), Alphabet (GOOG) (GOOGL), Amazon (AMZN), Nvidia (NVDA), Meta Platforms (META), and Tesla (TSLA). These technology titans are developing products related to Artificial IntelligencTradingKey
15 hours ago
Bitcoin Price Prediction 2029-2035: Institutional Accumulation and the U.S. Treasury’s Strategic Reserve Pivot
Explore the 2026 Bitcoin landscape: From the U.S. Strategic Reserve and Michael Saylor’s $75B war chest to Cathie Wood’s 2030 forecast. Is BTC the new Digital Gold?TradingKey
Fri, Feb 13
This $1 Trillion AI Stock Is Getting Ready for 2026: Is Meta a Good Buy?
When ads and commerce are factored in, Meta is building a long-term platform—in Augmented Reality and smart glasses — to get us closer to the future of AI. This device hardware business is less profitable than ads right now, but it could grow the company’s ecosystem and open up new ways for it to maTradingKey
Thu, Feb 12
Is SaaS Dead? The Truth Behind the Software Meltdown, the Missing Floor, and the Peak That’s Not Coming Back
TradingKey - A trillion dollars just vanished from software stocks—this piece breaks down who AI is really killing, who quietly benefits, and why cheap SaaS may be the biggest value trap of this cycle.TradingKey
Thu, Feb 12
